← All trials
NCT04226248
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 2, 2020
- Primary completion
- Nov 12, 2021
- Completion date
- Nov 12, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BristolLead sponsor
- University of BristolOverall official - principal investigator
- University of BathCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.